

II. REMARKS

Preliminary Remarks

The applicants would like to thank the examiner for the indication of allowable subject matter in claims 9 and 10.

Upon entry of this Amendment, claims 1, 2, 9, 10, and 26 are pending, of which claims 1, 9, and 26 are independent. Claim 1 is amended to delete the compounds of Groups IA and VA), as well as their sub-groups. Claim 2 is amended to the method of Claim 1, in which R is chosen from groups IIA) and IVA). Claims 5 and 21 to 25 were previously canceled. Claims 3, 4, 6, and 11 to 20 were withdrawn from consideration and are canceled by the current Amendment.

The applicants respectfully request entry of this response pursuant to 37 C.F.R. §1.116, in that if the examiner maintains the claim rejections, this response places the claims in better form for appeal. This response is filed within the statutory period for response and is accompanied by a petition for a one-month extension of time and the appropriate fees. The applicants respectfully request reconsideration and allowance of the present application.

Patentability Remarks

Rejection under 35 U.S.C. §103 –

Claims 1 to 2 were rejected under 35 U.S.C. §103(a) as being unpatentable over Scherrer *et al.* (U.S. Pat. No. 3,313,848) and Matji *et al.* (WO 94/04484) in view of Persson *et al.* (CA 117:45429) and Chung *et al.* (CA 125:105692). The applicants respectfully traverse in view of the preceding amendments and succeeding remarks.

The examiner alleges that Scherrer *et al.* and Matji *et al.* describe compounds similar to those claimed for treating inflammation, while Persson *et al.* and Chung *et al.* teach NO donors for increasing time to micturition and bladder pressure threshold, and therefore, the disclosed compounds are known to be useful for treating urinary incontinence.

Claims 1 and 2, as amended, exclude any compounds described in either Scherrer *et al.* or Matji *et al.* With respect to the remaining compounds, the applicants respectfully direct the examiner's attention to The Merck Index, 13th Ed., Therapeutic Category and Biological Activity Index (enclosed), which shows that flurbiprofen is an anti-inflammatory nonsteroidal drug, arylpropionic acid derivative.

NO-flurbiprofen belongs to group IIA) of claim 1 and the applicants respectfully submit that it is representative of all the arylpropionic acid derivatives falling within groups IIA) and IIIA), including suprofen (Formula II), carprofen (XXI), ketoprofen (IV), fenoprofen (VII), thiaprofenic acid (XXXV), indoprofen (VI), flurbiprofen (IX); pranoprofen (IIIa), bermoprofen (XXX), CS-670 (XXXI), zaltoprofen (XXXVI), naproxen (II), loxoprofen (X), and ibuprofen (III).

All the compounds above reported belong to the same therapeutically class, i.e. anti-inflammatory nonsteroidal drugs and containing $-\text{CH}(\text{CH}_3)-\text{COOH}$. Therefore, NO-flurbiprofen is representative of this class of compounds.

Furthermore, the present invention is concerned with the administration of compounds $\text{A}-\text{X}_1-\text{NO}_2$ as claimed, for the treatment of urinary incontinence. Persson *et al.* and Chung *et al.*, however, teach that the disclosed NO donors require electric stimulation or UV light to work. Accordingly, those of ordinary skill in the art would have no motivation to combine the NO donors of Persson *et al.* and Chung *et al.* with the compounds of Scherrer *et al.* and Matji *et al.* for the treatment of urinary incontinence as claimed. Indeed, due to the necessity of electric stimulation or UV light, those of ordinary skill in the art would have no motivation to combine reference teachings, so as to arrive at the claimed method (Manual of Patent Examining Procedure §2143.01).

In order for the examiner to set forth a *prima facie* case of obviousness he is required to consider each reference as a whole, taking into account all teachings disclosed therein. It is impermissible to pick and choose only those teachings that might support a rejection. The applicants respectfully submit that the examiner has engaged in just such an impermissible picking and choosing of reference teachings.

The combination of reference teachings as a whole, would result in inoperative NO donors. The claimed method does not envision electric stimulation or UV light, and

those of ordinary skill in the art would recognize that patients in such a treatment could not be electrically stimulated or UV illuminated during the administration of the claimed compounds. In contrast, in Persson *et al.* and Chung *et al.*, electric stimulation or UV light is introduced during *in vitro* experiments on small strips of rat/pig muscle. Clearly, this is something other than the claimed invention, and provides no motivation concerning the method of treatment claimed.

The applicants respectfully submit that claims 1 and 2 are not unpatentable over Scherrer *et al.* and Matji *et al.* in view of Persson *et al.* and Chung *et al.* and request withdrawal of this rejection.

Finally, the applicants respectfully draw the examiner's attention to claim 26. This claim was added in the Supplemental Preliminary Amendment filed on September 8, 2003. As this claim is not the subject of any rejections, the applicants believe that it is allowable.


III. CONCLUSION

In view of the amendments and remarks above, the applicants respectfully submit that this application is in condition for allowance and request favorable action thereon.

In the event this response is not timely filed, the applicants hereby petition for an appropriate extension of time. The fee for this extension, along with any other additional fees which may be required with respect to this response, may be charged to Deposit Account No. 01-2300, referencing Attorney Docket No. 026220-00031.

Respectfully submitted,

ARENT FOX PLLC


Gautam Prakash, Ph.D.
Registration No.: 53,481
Direct Telephone No.: 202-857-6057

Customer No.: **004372**

1050 Connecticut Avenue, N.W.
Washington, D.C. 20036-5339

Telephone No.: 202-857-6000
Facsimile No.: 202-638-4810

GP/ccd

THE MERCK INDEX

AN ENCYCLOPEDIA OF
CHEMICALS, DRUGS, AND BIOLOGICALS

THIRTEENTH EDITION

Editorial Staff

Maryadele J. O'Neil, *Senior Editor*

Ann Smith, *Senior Associate Editor*

Patricia E. Heckelman, *Associate Editor*

John R. Obenchain Jr., *Editorial Assistant*

Jo Ann R. Gallipeau, *Technical Assistant*

Mary Ann D'Arecca, *Administrative Associate*

Susan Budavari, *Editor Emeritus*

*Published by
Merck Research Laboratories
Division of*

MERCK & CO., INC.
Whitehouse Station, NJ

2001

BEST AVAILABLE COPY

ANTIHYPERTHYROID (continued)

Sodium Perchlorate, 8726
 Thibenzazoline, 9983
 Thiobutital, 9393
 2-Thiouracil, 9442

ANTIHYPOTENSIVE

Ametizipium Methyl Sulfate, 392
 Angiotensin Amide *see* 634
 Dopamine, 3453
 Dimetofina, 3291
 Etilefalin, 3893
 Etilefin, 3897
 Gepefrine, 4413
 Metaraminol, 3957
 Methoxamine, 6017
 Midodrine, 6208
 Norepinephrine, 6727
 Pholodrine, 7415
 Synephrine, 9104

ANTIHYPOTHYROID

Thyroid, 9487
 Liothyronine, 5532
 Thyroidin, 9488
 Thyroxine, 9491
 Titracal, 9539
 TSH, 9870

ANTI-INFECTIONAL *see* Antineoplastic/Disinfectant**ANTI-INFLAMMATORY (GASTROINTESTINAL)**

Balsalazide, 947
 Mesalamine, 5931
 Olazaxine, 6911
 Sulfasalazine, 9028

ANTI-INFLAMMATORY (NONSTEROIDAL) *see also* Antiarthritic/Antirheumatic**Aminoarylcarboxylic Acid Derivatives**

Benfenamic Acid, 3614
 Bufexamate, 3907
 Flufenamic Acid, 4158
 Isometin, 5211
 Mefenamic Acid, 5802
 Mefenamic Acid, 5821
 Niflumic Acid, 6557
 Talmifumate, 9154
 Terephthalamate, 9244
 Tolfenamic Acid, 9390

Arylmalic Acid Derivatives

Acetofenac, 22
 Acemuric, 28
 Alclofenac, 218
 Amfenac, 393
 Amokmetin Quacil, 600
 Bromfenac, 1374
 Bufexamac, 1461
 Clamfenac, 2316
 Clopirac, 2423
 Diclofenac, 3108
 Endolac, 3903
 Felbinac, 3979
 Fencloric Acid, 3996
 Fencloric, 4031

Glucametin, 4461
 Ibufenac, 4903
 Indomethacin, 4990
 Isospac, 5239
 Loazolac, 5387
 Metazinic Acid, 6160
 Mofezolac, 6254
 Oxametazine, 6983
 Pirazolac, 7371
 Propylmetacin, 7865
 Sulfadac, 9072
 Tiacamide, 9500
 Tolmetin, 9593
 Tropein, 9848
 Zomexin, 10243

Arylbutyric Acid Derivatives

Bumadizon, 1470
 Butibufen, 1521
 Fenbuten, 3990
 Xenobuta, 10128

Arylcarboxylic Acids

Clidanac, 2174
 Ketorolac, 5324
 Ticoridine, 9526

Arylpropionic Acid Derivatives

Alminoprofen, 297
 Benoxaprofen, 1044
 • Benoxaprofen, 1162
 • Carprofen, 1878
 • Fenoprofen, 4007
 Flunoxaprofen, 4174
 • Flurbiprofen, 4225
 • Ibuprofen, 4906
 Ibuprofen, 4907
 • Indoprofen, 4991
 • Ketoprofen, 5322
 • Loxoprofen, 5611
 • Naproxen, 6443
 Oxaprofen, 6993
 Piroxicam, 7503
 Piroxicam, 7591
 • Pransoprofen, 7796
 Protizinc Acid, 7983
 • Suprofen, 9093
 • Tiaprofenic Acid, 9498
 Ximoprofen, 10133
 • Zalcoprofen, 10166

Pyrazoles

Difenamizole, 3159
 Epirazole, 3653

Pyrazolones

Apazone, 733
 Benzpiperylon, 1120
 Faprazone, 4040
 Mofebutazone, 6252
 Morazone, 6290
 Oxyphenbutazone, 7041
 Phenylbutazone, 7361
 Piphebutazone, 7338
 Propylphenazone, 7963
 Ramifenazone, 8193
 Suxibutazone, 9100
 Thiazolinobutazone, 9379

Salicylic Acid Derivatives

Acetaminosalol, 49
 Aspirin, 856
 Balsalazide, 947
 Benoxylate, 1043
 Calcium Acetylsalicylate, 1046
 Difunisal, 3170
 Fendosal, 3998

Genisic Acid, 4409
 Glycol Salicylate, 4512
 Imidazole Salicylate, 4936
 Lysine Acetylsalicylate, 3677
 Micalamine, 5931
 Morpholine Salicylate *see* 634
 1-Naphthyl Salicylate, 6440
 Olazaxine, 6911
 Parsamide, 7117
 Phenyl Acetylsalicylate, 7354
 Phenyl Salicylate, 7394
 Salacetamide, 8398
 Salicylamide O-Acetic Acid, 8408
 Salicylsulfuric Acid, 8413
 Salsalate, 8418
 Sodium Salicylate *see* 8411
 Sulfasalazine, 9028

Thiazinecarboxamides

Amproxicam, 592
 Dexicam, 3491
 Isoxicam, 5260
 Lornoxicam, 5603
 Piroxicam, 7589
 Tenoxicam, 9223

Others

• Acetamidocaproic Acid, 467
 S-Adenosylmethionine, 137
 3-Amino-4-hydroxybutyric Acid, 443
 Bendazac, 1052
 Benzydamine, 1124
 • Bisabolol, 1241
 Bucetone, 1451
 Celecoxib, 1968
 Difenpiramide, 3162
 Dinazol, 3403
 Emorlatone, 3594
 Etanercept, 3747
 Fepradinol, 4039
 Guaisulone, 4570
 Inftiximab, 4993
 Interleukin-10, 5020
 Loxipitant, 5493
 Nabumetone, 6369
 Nimesulide, 6376
 Oxaceprol, 6971
 Paraxylene, 7101
 Paricalc, 7254
 Proquazone, 7965
 Rofecoxib, 8330
 Superoxide Dismutase, 9092
 Tenidap, 9221

ANTI-INFLAMMATORY (STEROIDAL) *see* Glucocorticoids**ANTILEPROTIC *see* Antibacterial (Leprosy)****ANTILEUKEMIC *see* Antineoplastic****ANTILIPEMIC *see* Antihyperlipidemic****ANTILIPIDEMIC *see* Antihyperlipidemic****ANTIMALARIAL**

Acadapone, 23
 Amodiaquin, 576
 Artemether, 822
 Artesunate, 823
 Artemether, 824
 Artemisinin, 826
 Artesunate, 827
 Beberline, 1017
 Berberine, 1157
 Chirata, 2071
 Chloroquine, 2106
 Chloroquine, 2182
 Chloroquine, 2203
 Cinchona, 2305
 Cinchonidine, 2307
 Cinchonine, 2308
 Cycloguanil, 2750
 Gentianin, 4408
 Halofantrine, 4609
 Hydroxychloroquine, 48
 Lumefantrine, 3619
 Mefloquine Hydrochloride, 7070
 Pamaquine, 7070
 Primaquine, 7833
 Pyrimethamine, 8075
 Pyronaridine, 8093
 Quinacrine, 8132
 Quinidine, 8150
 Quinine, 8151
 Quinidine, 8159
 Quinolone, 8160
 Sodium Arsenite, Dibutyl
 Tafenoquine, 9120

ANTIMANIC

Lithium Acetate, 5543
 Lithium Carbonate, 5545
 Lithium Chloride, 5550
 Lithium Citrate, 5552
 Lithium Sulfate, 5563
 Valproic Acid, 9979

ANTIMETHEMOGLOBINIC

Methylene Blue, 6085

ANTIMIGRAINE

Almotriptan, 301
 Alpropride, 309
 Dihydroergotamine, 319
 Dolasetron, 3445
 Domnamine, 3461
 Ertipran, 3577
 Ergocornine, 3678
 Ergocornine, 3679
 Ergocryptine, 3682
 Ergot, 3695
 Ergotamine, 3696
 Fenazone, 4256
 Gonazolone, 4577
 Lisdol, 5540
 Lometidine, 5584
 Methysergide, 6158
 Naratriptan, 6446
 Oxetorone, 7003
 Piroxyline, 7398
 Rizatriptan, 8324
 Sumatriptan, 9088
 Valproic Acid, 9979
 Zolmitriptan, 10241